Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Sales (2017 - 2025)

Historic Return on Sales for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 0.01%.

  • Akebia Therapeutics' Return on Sales rose 5400.0% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year decrease of 31900.0%. This contributed to the annual value of 0.43% for FY2024, which is 47600.0% up from last year.
  • As of Q3 2025, Akebia Therapeutics' Return on Sales stood at 0.01%, which was up 5400.0% from 0.0% recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Return on Sales peaked at 0.23% during Q2 2022, and registered a low of 1.59% during Q2 2021.
  • Moreover, its 5-year median value for Return on Sales was 0.49% (2024), whereas its average is 0.57%.
  • Examining YoY changes over the last 5 years, Akebia Therapeutics' Return on Sales showed a top increase of 27700bps in 2021 and a maximum decrease of -6500bps in 2021.
  • Akebia Therapeutics' Return on Sales (Quarter) stood at 1.22% in 2021, then soared by 90bps to 0.12% in 2022, then skyrocketed by 96bps to 0.0% in 2023, then plummeted by -10158bps to 0.49% in 2024, then skyrocketed by 102bps to 0.01% in 2025.
  • Its last three reported values are 0.01% in Q3 2025, 0.0% for Q2 2025, and 0.11% during Q1 2025.